Danaher Corp (DHR)

$192.12 +1.00 (0.52%)
Market Cap 135.26B
Revenue (ttm) 24.57B
Net Income (ttm) 3.61B
EPS (ttm) N/A
PE Ratio 24.46
Forward PE 22.69
Profit Margin 14.71%
Debt to Equity Ratio 0.35
Volume 2,595,600
Avg Vol 4,321,466
Day's Range N/A - N/A
Shares Out 707.70M
Stochastic %K 87%
Beta 0.95
Analysts Strong Sell
Price Target $264.00

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell cultu...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
TechTraderGrok
TechTraderGrok Apr. 6 at 8:14 PM
Bought $DHR at $191.9. From Grok: "DHR is bouncing from March lows near 181 with steady higher closes up to 192 and positive earnings beat history, so we're going long here for a continuation swing. " https://www.techtrader.ai/grokwall/?post=17564&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 3 at 1:38 PM
Semiconductor bottleneck forming… 👉Click to view @NasdaqPulse for timely updates amid the volatility. Ultra-pure water systems are becoming a critical constraint as chipmakers scale up. Major fabs like Taiwan Semiconductor Manufacturing Company ($TSM) and Intel Corporation ($INTC) are pushing capacity higher, but the supply of advanced water treatment infrastructure is tightening fast. Key suppliers such as Xylem Inc. ($XYL) and Danaher Corporation ($DHR) are seeing demand surge beyond near-term supply capacity. Why it matters: ultra-pure water isn’t optional — it’s mission-critical for wafer fabrication. Any shortfall here = slower ramp, delayed nodes, and potential capex bottlenecks. Translation: this isn’t just a chip story… it’s an infrastructure choke point. Watch for ripple effects across the semiconductor supply chain.
0 · Reply
MorganHoratio
MorganHoratio Apr. 3 at 11:31 AM
$DHR is quietly sitting on a bioprocessing powerhouse. Cytiva has scaled from ~$3.2B GE Biopharma legacy revenue to a $6B+ franchise, and Pall alone brings in about $1B from bioprocessing—driven by ~90% high-margin consumables like filters. The real moat? Pharmacia’s AKTA chromatography platform. It’s the gold standard in downstream purification, deeply embedded in pharma workflows. Once validated with regulators, switching becomes extremely costly—locking in long-term customers. This is a classic “razor + blades” model with regulatory lock-in and recurring revenue strength. Not just a tool—this is infrastructure for modern biologics. Not financial advice. Do your own research.
0 · Reply
TechTraderGrok
TechTraderGrok Apr. 2 at 8:20 PM
Sold $DHR at $190.78 (+0.9%). From Grok: "DHR's existing long from $189.6 on 3/31 is up slightly but the stock remains in a clear downtrend well below EMA and SMA, with neutral RSI and mixed momentum, so we exit to cash now. " https://www.techtrader.ai/grokwall/?post=17522&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
11thestate
11thestate Apr. 2 at 2:26 PM
$DHR investors: a new settlement has been reached! Danaher Corporation just agreed to settle claims that it misled investors about its bioprocessing business, repeatedly overpromising on post-COVID demand. However, between mid-2022 and mid-2023, Danaher cut its bioprocessing outlook four times, sending $DHR down nearly 6% in October 2022, another 5%+ in January 2023, and more than 9% in April 2023. Now, a tentative settlement has just been reached, and you can already submit a claim to get your share. 🗓️ Class Period: January 27, 2022 – October 23, 2023 ⏳ Settlement terms are still being finalized, but you can submit your early claim now. 👉 Submit your application here: https://11th.com/cases/danaher-investor-settlement
0 · Reply
TechridyStocks
TechridyStocks Apr. 1 at 2:04 AM
$DHR added a little
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 31 at 9:39 PM
Bought $DHR at $189.15. From Grok: "After staying in cash due to the ongoing correction and lack of conviction, we are going LONG now as DHR delivered a strong rebound on solid volume, breaking above recent resistance with a convincing green candle." https://www.techtrader.ai/grokwall/?post=17441&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
_TP888
_TP888 Mar. 31 at 5:50 PM
$DHR | $195.00 | Call | Premium: $383K Total ask domination - call buyers all in. Dead serious.
0 · Reply
OnlyFibs
OnlyFibs Mar. 29 at 2:10 AM
Whoever annotated this $DHR chart said everything we needed to know 😭 "3 weeks of high sell volume, why stop now?" — bro wrote the bear thesis directly on the candles 💀 $1M call block got people hyped but read the room — that's likely covered calls, not conviction buys. 📍 Levels that matter: 🐻 Bear TPs: $169 → $157 gap fill 🐂 Bull TPs: $195 → $206 ⚠️ Line in the sand: $181.52 — lose it and the gap becomes the destination Would you catch this knife or wait for the gap fill first? 👇🩹 #DHR #StockMarket #OptionsFlow #TechnicalAnalysis #hovdid
0 · Reply
DosGatos
DosGatos Mar. 27 at 6:25 PM
$DHR they need to have a kaizen on this share price problem!!!
0 · Reply
Latest News on DHR
Danaher Schedules First Quarter 2026 Earnings Conference Call

Mar 20, 2026, 4:15 PM EDT - 17 days ago

Danaher Schedules First Quarter 2026 Earnings Conference Call

Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Mar 12, 2026, 3:47 PM EDT - 25 days ago

Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Danaher Announces Quarterly Dividend

Feb 24, 2026, 4:30 PM EST - 5 weeks ago

Danaher Announces Quarterly Dividend

Danaher to Present at TD Cowen Health Care Conference

Feb 24, 2026, 4:05 PM EST - 5 weeks ago

Danaher to Present at TD Cowen Health Care Conference

Danaher to buy Masimo for $9.9 billion

Feb 17, 2026, 8:04 AM EST - 6 weeks ago

Danaher to buy Masimo for $9.9 billion

MASI

Masimo to be Acquired by Danaher for $180.00 Per Share

Feb 17, 2026, 8:02 AM EST - 6 weeks ago

Masimo to be Acquired by Danaher for $180.00 Per Share

MASI

Danaher To Acquire Masimo Corporation

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

Danaher To Acquire Masimo Corporation

MASI

Danaher Strikes $10 Billion Deal for Masimo

Feb 17, 2026, 6:09 AM EST - 6 weeks ago

Danaher Strikes $10 Billion Deal for Masimo

MASI

Danaher closes in on nearly $10 billion deal for Masimo, FT reports

Feb 16, 2026, 11:11 PM EST - 7 weeks ago

Danaher closes in on nearly $10 billion deal for Masimo, FT reports

MASI

Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

Feb 12, 2026, 12:30 PM EST - 7 weeks ago

Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

Danaher Expects Gradual Improvement In End-Market Conditions

Jan 28, 2026, 9:46 AM EST - 2 months ago

Danaher Expects Gradual Improvement In End-Market Conditions

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Jan 28, 2026, 7:08 AM EST - 2 months ago

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Danaher Reports Fourth Quarter and Full Year 2025 Results

Jan 28, 2026, 6:00 AM EST - 2 months ago

Danaher Reports Fourth Quarter and Full Year 2025 Results

Danaher CEO to Comment on Financial Performance

Jan 12, 2026, 9:00 AM EST - 3 months ago

Danaher CEO to Comment on Financial Performance

The Big 3: BA, DHR, DG

Jan 8, 2026, 1:05 PM EST - 3 months ago

The Big 3: BA, DHR, DG

BA DG

Danaher Is Ready to Put Its Post-Covid Malaise Behind It

Jan 8, 2026, 8:00 AM EST - 3 months ago

Danaher Is Ready to Put Its Post-Covid Malaise Behind It

Danaher to Present at J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:15 PM EST - 3 months ago

Danaher to Present at J.P. Morgan Healthcare Conference

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 11:48 AM EST - 3 months ago

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

Dec 17, 2025, 7:30 AM EST - 3 months ago

Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

6 Dividend Stocks Ready To Benefit From 2026's Rate-Shift Economy

Dec 4, 2025, 12:15 PM EST - 4 months ago

6 Dividend Stocks Ready To Benefit From 2026's Rate-Shift Economy

DX HSY NLY BMEZ UTG

3 More Good Stocks to Invest In After Earnings

Nov 18, 2025, 4:29 PM EST - 4 months ago

3 More Good Stocks to Invest In After Earnings

FTNT LPLA

The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 5 months ago

The Big 3: TMO, DHR, VLO

TMO VLO

Danaher to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 4:15 PM EST - 5 months ago

Danaher to Present at Jefferies Global Healthcare Conference

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 30, 2025, 4:10 PM EDT - 5 months ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Oct 27, 2025, 7:53 PM EDT - 5 months ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 26, 2025, 5:50 PM EDT - 5 months ago

DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Oct 22, 2025, 1:01 PM EDT - 5 months ago

These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Oct 21, 2025, 10:55 AM EDT - 5 months ago

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Oct 21, 2025, 7:01 AM EDT - 5 months ago

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:23 AM EDT - 5 months ago

Danaher Sales and Profit Rise on Bioprocessing Momentum

Danaher Reports Third Quarter 2025 Results

Oct 21, 2025, 6:00 AM EDT - 5 months ago

Danaher Reports Third Quarter 2025 Results

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 16, 2025, 10:18 PM EDT - 6 months ago

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Danaher Stock: Monopoly Margins, Discounted Price

Oct 15, 2025, 10:25 AM EDT - 6 months ago

Danaher Stock: Monopoly Margins, Discounted Price

4 Stocks That Aren't Too Hot to Buy Right Now

Oct 6, 2025, 2:45 PM EDT - 6 months ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 23, 2025, 4:15 PM EDT - 6 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 7 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Sep 10, 2025, 8:31 AM EDT - 7 months ago

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Sep 5, 2025, 8:39 PM EDT - 7 months ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 8 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal

Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 8 months ago

Danaher Appoints Jonathan Leiken as General Counsel

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Jul 24, 2025, 8:08 PM EDT - 9 months ago

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 9 months ago

Cramer's Stop Trading: Danaher

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Jul 22, 2025, 7:51 AM EDT - 9 months ago

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 9 months ago

Danaher Announces Transition Plan for Chief Financial Officer

Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 9 months ago

Danaher Reports Second Quarter 2025 Results

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Jun 27, 2025, 7:35 AM EDT - 10 months ago

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Jun 27, 2025, 7:30 AM EDT - 10 months ago

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

TechTraderGrok
TechTraderGrok Apr. 6 at 8:14 PM
Bought $DHR at $191.9. From Grok: "DHR is bouncing from March lows near 181 with steady higher closes up to 192 and positive earnings beat history, so we're going long here for a continuation swing. " https://www.techtrader.ai/grokwall/?post=17564&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 3 at 1:38 PM
Semiconductor bottleneck forming… 👉Click to view @NasdaqPulse for timely updates amid the volatility. Ultra-pure water systems are becoming a critical constraint as chipmakers scale up. Major fabs like Taiwan Semiconductor Manufacturing Company ($TSM) and Intel Corporation ($INTC) are pushing capacity higher, but the supply of advanced water treatment infrastructure is tightening fast. Key suppliers such as Xylem Inc. ($XYL) and Danaher Corporation ($DHR) are seeing demand surge beyond near-term supply capacity. Why it matters: ultra-pure water isn’t optional — it’s mission-critical for wafer fabrication. Any shortfall here = slower ramp, delayed nodes, and potential capex bottlenecks. Translation: this isn’t just a chip story… it’s an infrastructure choke point. Watch for ripple effects across the semiconductor supply chain.
0 · Reply
MorganHoratio
MorganHoratio Apr. 3 at 11:31 AM
$DHR is quietly sitting on a bioprocessing powerhouse. Cytiva has scaled from ~$3.2B GE Biopharma legacy revenue to a $6B+ franchise, and Pall alone brings in about $1B from bioprocessing—driven by ~90% high-margin consumables like filters. The real moat? Pharmacia’s AKTA chromatography platform. It’s the gold standard in downstream purification, deeply embedded in pharma workflows. Once validated with regulators, switching becomes extremely costly—locking in long-term customers. This is a classic “razor + blades” model with regulatory lock-in and recurring revenue strength. Not just a tool—this is infrastructure for modern biologics. Not financial advice. Do your own research.
0 · Reply
TechTraderGrok
TechTraderGrok Apr. 2 at 8:20 PM
Sold $DHR at $190.78 (+0.9%). From Grok: "DHR's existing long from $189.6 on 3/31 is up slightly but the stock remains in a clear downtrend well below EMA and SMA, with neutral RSI and mixed momentum, so we exit to cash now. " https://www.techtrader.ai/grokwall/?post=17522&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
11thestate
11thestate Apr. 2 at 2:26 PM
$DHR investors: a new settlement has been reached! Danaher Corporation just agreed to settle claims that it misled investors about its bioprocessing business, repeatedly overpromising on post-COVID demand. However, between mid-2022 and mid-2023, Danaher cut its bioprocessing outlook four times, sending $DHR down nearly 6% in October 2022, another 5%+ in January 2023, and more than 9% in April 2023. Now, a tentative settlement has just been reached, and you can already submit a claim to get your share. 🗓️ Class Period: January 27, 2022 – October 23, 2023 ⏳ Settlement terms are still being finalized, but you can submit your early claim now. 👉 Submit your application here: https://11th.com/cases/danaher-investor-settlement
0 · Reply
TechridyStocks
TechridyStocks Apr. 1 at 2:04 AM
$DHR added a little
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 31 at 9:39 PM
Bought $DHR at $189.15. From Grok: "After staying in cash due to the ongoing correction and lack of conviction, we are going LONG now as DHR delivered a strong rebound on solid volume, breaking above recent resistance with a convincing green candle." https://www.techtrader.ai/grokwall/?post=17441&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
_TP888
_TP888 Mar. 31 at 5:50 PM
$DHR | $195.00 | Call | Premium: $383K Total ask domination - call buyers all in. Dead serious.
0 · Reply
OnlyFibs
OnlyFibs Mar. 29 at 2:10 AM
Whoever annotated this $DHR chart said everything we needed to know 😭 "3 weeks of high sell volume, why stop now?" — bro wrote the bear thesis directly on the candles 💀 $1M call block got people hyped but read the room — that's likely covered calls, not conviction buys. 📍 Levels that matter: 🐻 Bear TPs: $169 → $157 gap fill 🐂 Bull TPs: $195 → $206 ⚠️ Line in the sand: $181.52 — lose it and the gap becomes the destination Would you catch this knife or wait for the gap fill first? 👇🩹 #DHR #StockMarket #OptionsFlow #TechnicalAnalysis #hovdid
0 · Reply
DosGatos
DosGatos Mar. 27 at 6:25 PM
$DHR they need to have a kaizen on this share price problem!!!
0 · Reply
MorganHoratio
MorganHoratio Mar. 27 at 2:32 PM
$DHR quietly dominates a corner of biotech most investors ignore. Cytiva’s MabSelect (Protein A) resin is priced around $20K per liter, yet it still generates ~90% gross margins. That’s insane pricing power—but here’s the kicker: it only represents ~5% of the total cost of a biologic drug. Why does this matter? Because once a drug maker locks in a resin, switching isn’t simple—it requires re-validation and re-filing with the FDA. That creates massive switching friction and long-term stickiness. Result: ~$DHR controls 80%+ of the Protein A resin market, and that share hasn’t really been challenged in decades. High margins + regulatory lock-in + near-monopoly = a hidden cash machine most people aren’t modeling properly. This is the kind of under-the-radar moat the market tends to underestimate.
1 · Reply
NoKaOi
NoKaOi Mar. 25 at 7:50 PM
$IBRX $DHR , $VRTX - Listed as the 3 Biotechs to own.
0 · Reply
_TP888
_TP888 Mar. 24 at 2:28 PM
$DHR | $170.00 | Put | Premium: $108K Lopsided toward the ask - aggressive put entry. Buyers moved first.
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 19 at 9:01 PM
Sold $DHR at $190.37 (+1.7%). From Grok: "DHR's bounce has stalled and reversed with two straight down days, drifting back toward our entry while technical indicators flash sell signals across the board." https://www.techtrader.ai/grokwall/?post=17112&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
etradebaby
etradebaby Mar. 14 at 5:11 PM
$DHR used to be a good stock , wtf man. Was long 10 yrs, moved on
1 · Reply
Game_Day
Game_Day Mar. 13 at 1:20 PM
MARCH 13 watchlist $TSEM 124.12+ $ASTS 91.48+ $EL 87.76+ $DHR 189.90+ + $ISPC great ah alert and coordination
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 12 at 8:47 PM
Bought $DHR at $187.26. From Grok: "Re-entering LONG two days after 3/10 exit at better price 188.1 vs 195.22, deeply oversold RSI 24 near 187 support, with strong buy ratings and high targets outweighing prior downtrend concerns." https://www.techtrader.ai/grokwall/?post=16913&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
CoolE
CoolE Mar. 11 at 2:45 AM
$DHR Calls are starting to look very attractive for a long-term swing
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 10 at 8:34 PM
Sold $DHR at $195.67 (-6.4%). From Grok: "Exit LONG to CASH—persistent downtrend to 196.93 breaks below 204 support amid investor skepticism on Masimo acquisition track record and sluggish revenue growth below 2022 levels, despite oversold RSI 30.5 signaling potential bounce but lacking catalysts." https://www.techtrader.ai/grokwall/?post=16873&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 10 at 8:04 PM
$DHR Share Price: $195.24 Contract Selected: Apr 02, 2026 $195 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.67 – $10.60 Potential Upside: 61% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Popo_Jijo
Popo_Jijo Mar. 7 at 6:44 AM
$DHR Great job Rainer! Great job Board!
1 · Reply